Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jan 21;14(2):251-9.
doi: 10.1002/cbic.201200582. Epub 2013 Jan 10.

Capture of uropathogenic E. coli by using synthetic glycan ligands specific for the pap-pilus

Affiliations

Capture of uropathogenic E. coli by using synthetic glycan ligands specific for the pap-pilus

Hailemichael O Yosief et al. Chembiochem. .

Abstract

Biotinylated mono- and biantennary di-/trisaccharides were synthesized to evaluate their ability to capture E. coli strains that express pilus types with different receptor specificities. The synthesized biotinylated di-/trisaccharides contain Galα(1→4)Gal, Galα(1→4)GalNHAc, GalNHAcα(1→4)Gal, Galα(1→4)Galβ(1→4)Glc and GalNHAcα(1→4)Galβ(1→4)Glc as carbohydrate epitopes. These biotinylated oligosaccharides were immobilized on streptavidin-coated magnetic beads, and incubated with different strains of live E. coli. Capturing ability was assessed by using a luciferase assay that detects bacterial ATP. The trisaccharides containing Galα(1→4)Galβ(1→4)Glc and the disaccharides containing Galα(1→4)Gal as the epitopes exhibited strong capturing ability for uropathogenic E. coli strains with the pap pilus genotype, including CFT073, J96 and J96 pilE. The same ligands failed to capture E. coli strains with fim, prs, or foc genotypes. Uropathogenic CFT073 was also captured moderately by biantennary disaccharides containing a GalNHAc moiety at the reducing end; however, other saccharides containing GalNHAc at the nonreducing end did not capture the CFT073 strain. These synthetic glycoconjugates could potentially be adapted as rapid diagnostic agents to differentiate between different E. coli pathovars.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Bacterial-induced aggregation of GC-4b coated beads
CFT073 (A and B) and ORN178 (C and D) were incubated with GC-4b coated beads. A) Visual aggregation of the beads incubated with CFT073 was observed, as documented by light microscopy. B) In ESEM CFT073 bacteria were seen bound to the beads (arrows). C) No aggregation was observed for beads incubated with ORN178. D) In ESEM no bacteria are seen bound to the beads incubated with ORN178.
Figure 2
Figure 2. Binding of E. coli strains to the biantennary Pk trisaccharide (GC-4b)
Error bars represent mean ± SEM of three independent experiments. Statistical analysis using a student t-test was performed comparing the binding of each E. coli strain to GC-4b (*P < 0.05).
Figure 3
Figure 3. Capturing of CFT073 with the panel of glycans
Error bars represent mean ±standard error of three independent experiments. Statistical analysis using a student t-test was performed comparing the binding and capturing ability of each ligand; * no statistical differences between the group (P > 0.05), ** significantly reduced binding compared to * group (P < 0.05).
Scheme 1
Scheme 1. Representation of the synthesized biotinylated glycoconjugates
The compounds comprise of di or trisaccharides attached to a biotinylated monomeric and dimeric scaffold via a 6-carbon spacer. The black eclipse represents the carbohydrate epitope.
Scheme 2
Scheme 2. Synthesis of GC-1a and GC-1b Reagents and conditions
a) CH2Cl2, AgOTf, p-NO2PhSCl, TTBP, −78°C, 60% b) PdCl2, NaOAc, AcOH, H2O, rt, 54% c) Pd(OH)2, H2, EtOAc / EtOH, rt , 67%, d) Ac2O, pyridine, DMAP, 0°C to rt , 57% e) H2NNH2.HOAc, THF, rt, 63% f) K2CO3, CH2Cl2, Cl3CCN, rt, 77% g) CH2Cl2, HO(CH2)6Cl, TMSOTf, −30°C to rt, 55% h) CuSO4.5H2O, C6H7O6Na, THF/H2O, 70% i) MeOH, NaOMe, rt, quantitative j) CuSO4.5H2O, C6H7O6Na, THF/H2O, 70% k) MeOH, NaOMe, rt quantitative.
Scheme 3
Scheme 3. Attempted synthesis of GC-2a and GC-2b
Reagents and conditions. a) CH2Cl2, TMSOTf, -30°C to rt, 90% b)NaOMe, MeOH, rt, 93% c) PhCH(OMe)2, p-TsOH, THF, 76% d) NaH, BnBr, THF, reflux, 62% e) NaCNBH3, HCl.Et2O, THF, 73% f) CH2Cl2, TMSOTf, −30°C, 62% g) AcSH, 46% h) DMF, NaN3, 90% l) CuSO4.5H2O, C6H7O6Na, THF/H2O, 70% j) i.MeOH, NaOMe, rt ii. Pd (OH)2, H2, EtOH/EtOAc, k) Na, NH3
Scheme 4
Scheme 4. Synthesis of GC-2a and GC-2b
Reagents and conditions: a) i. NaOMe, MeOH, rt ii. Pd(OH)2, EtOH, H2, over two steps 75% b) i. Ac2O, Pyridine, DMAP, 78% ii. DMF, NaN3, 90% c) CuSO4.5H2O, C6H7O6Na, t-BuOH/H2O, 70% d) MeOH, NaOMe, rt ,90% e) CuSO4.5H2O, C6H7O6Na, t-BuOH/H2O, 70% f) MeOH, NaOMe, rt, 90%

Similar articles

Cited by

References

    1. Moriel DG, Rosini R, Seib LK, Serino L, Pizza M, Rappuoli R. mBio. 2012;3:e00118. - PMC - PubMed
    1. Croxen MA, Finlay BB. Nat.Rev.Microbiol. 2009;8:26. - PubMed
    1. Pieters JR. Medicinal Research Reviews. 2006;27:796. - PubMed
    1. Mulvey AM. Cellular Microbiology. 2002;4:257. - PubMed
    1. Madison B, Ofek I, Clegg S, Abraham NS. Infec. Immun. 1994;62:843. - PMC - PubMed

Publication types